Dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
In July 2009, there were a series of coordinated denial of service attacks against major government, news media, and financial websites in South Korea and the United States. While many thought the attack was directed by North Korea, one researcher traced the attacks to the United Kingdom. Security researcher Chris Kubecka presented evidence multiple European Union and United Kingdom companies unwittingly helped attack South Korea due to a W32.Dozer infections, malware used in part of the attack. Some of the companies used in the attack were partially owned by several governments, further complicating cyber attribution. In July 2011, the South Korean company SK Communications was hacked, resulting in the theft of the personal details (including names, phone numbers, home and email addresses and resident registration numbers) of up to 35 million people. A trojaned software update was used to gain access to the SK Communications network. Links exist between this hack and other malicious activity and it is believed to be part of a broader, concerted hacking effort. With ongoing tensions on the Korean Peninsula, South Korea's defense ministry stated that South Korea was going to improve cyber-defense strategies in hopes of preparing itself from possible cyber attacks. In March 2013, South Korea's major banks – Shinhan Bank, Woori Bank and NongHyup Bank – as well as many broadcasting stations – KBS, YTN and MBC – were hacked and more than 30,000 computers were affected; it is one of the biggest attacks South Korea has faced in years.
== Personal life == Liebling has made dubious claims that he turned to drug dealing during the 1970s, smuggling substances for the Medellin Cartel through Virginia and Colombia during the height of the Pablo Escobar era. He went as far as to claim he earned "tens of millions - sometimes in cash" during this period, but "blew it all, every dime of it on [his] own personal whoring, car-buying, house-buying for [his] friends, buying Ferraris and chinchilla coats and diamond rings for broads and flaunting it." In the 1980s, Liebling was in a relationship with Cheri Blade, a member of the band Chained Lace, with whom Pentagram often toured. He married Hallie Liebling on November 25, 2009. The couple welcomed their son, Robert Joseph Liebling, in 2010, when Hallie was 24 years old. They have been separated since around 2013.
However the amino acid tree seems to be more likely since it appears to be free from the synonymous codon-family bias affecting the nucleotide one. Most of the inferences based on amino acids sequences support a clade which includes Branchiopoda, Remipedia, Copepoda and Hexapoda (group A). Using the best amino acids substitution model, CATGTR, also Cephalocarida falls inside this group. In all the analyses group A (with or without Cephalocarida) is sister-group of a clade composed by Malacostraca, Oligostraca and Thecostraca (group B). The following diagram shows the tree resulting from the Dayhoff recoding.
) is 2.4×1034 years (in the decay channel into a positron and a neutral pion: p → e+ + π0). According to the Standard Model, the proton, a type of baryon, is stable because baryon number is conserved. Since protons are the lightest baryons in the model, they cannot decay into other particles on their own and are therefore stable. However, baryon number conservation is an accidental global symmetry of the Standard Model, not associated with any fundamental gauge symmetry, slightly violated by non-perturbative SU(2)L sphaleron effects, negligible at low temperatures but relevant in the early Universe. Positron emission and electron capture—forms of radioactive decay in which a proton becomes a neutron—are not proton decay, because in these processes the proton interacts with other particles within the atom. Grand Unified Theories (GUTs) explicitly break the baryon number symmetry, allowing protons to decay via the Higgs particle, magnetic monopoles, or new X bosons with a half-life in the range 1031 to 1036 years. For comparison, the universe is roughly 1.4×1010 (14 billion) years old, which is at least twenty orders of magnitude lower. Although at first glance it may seem nearly impossible to explore such long lifetimes, it is sufficient to monitor 1034 protons per year (with efficiency = 1) to be sensitive to average lifetimes of 1034 years. About 1034 protons are contained in approximately 30 kton of water, slightly more than the fiducial volume of the most sensitive experiment currently in operation, Super-Kamiokande.
Sources: en.wikipedia.org
In the early months of 2010, the economic crisis worsened due to the outbreak of the European debt crisis initiated by the Greek government-debt crisis. Immediately, the debt of the rest of the Eurozone countries which, as in the case of Spain, presented a strong deficit in their balance of payments began to be "attacked" in the financial markets with the consequent increase of the risk premium with respect to the German bond. Then the creditor countries of the Eurozone, led by Germany, imposed on the debtors to decrease their public spending to reduce the budget deficit. The European institutions' ultimatum to the Spanish government came at the European Council meeting of May 9, 2010. Three days later, on May 12, Prime Minister Rodríguez Zapatero announced in Congress a drastic cut in public spending to the tune of 15 billion euros – civil servants' salaries were reduced by 5%, pensions were frozen, investment in infrastructure was paralyzed, among other measures – thus consummating the turn of the Socialist government's economic policy towards "adjustment" policies. The consequence was to nip the incipient recovery in the bud and cause the fall into a new recession at the end of 2011, with the consequent increase in unemployment.
fibrinogen: lyophilised pooled human concentrate thrombin: This used to be of bovine origin; modern formulations contain human thrombin. The two components are mixed immediately before application. The formulations also contain calcium salts. Formulations from different manufacturers may also contain aprotinin, fibronectin, plasminogen, and factor XIII.
=== Tunnel vision === Sometimes, a viable suspect has been overlooked or simply ignored due to then-flimsy circumstantial evidence, the presence of a likelier suspect (who is later proven to be innocent), or simply for the focus itself to exclude other possibilities.
Bobby Flay's Bold American Food (Warner Books, May 31, 1994) – ISBN 978-0-4465-1724-9 Bobby Flay's From My Kitchen to Your Table (Clarkson Potter, March 31, 1998) – ISBN 978-0-517-70729-6 Bobby Flay's Boy Meets Grill (Hyperion, May 19, 1999) – ISBN 978-0-7868-6490-4 Bobby Flay Cooks American (Hyperion, September 30, 2001) – ISBN 978-0-7868-6714-1 Bobby Flay's Boy Gets Grill (Scribner, May 18, 2004) – ISBN 978-0-7432-5481-6 Bobby Flay's Grilling For Life (Scribner, May 3, 2005) – ISBN 978-0-7432-7272-8 Bobby Flay's Mesa Grill Cookbook (Clarkson Potter, October 16, 2007) – ISBN 978-0-3073-5141-8 Bobby Flay's Grill It! (Clarkson Potter, April 18, 2008) – ISBN 978-0-3073-5142-5 Bobby Flay's Burgers, Fries and Shakes (Clarkson Potter, April 11, 2009) – ISBN 978-0-3074-6063-9 Bobby Flay's Bar Americain Cookbook: Celebrate America's Great Flavors (Clarkson Potter, September 20, 2011) – ISBN 978-0-307-46138-4 Bobby Flay's Throwdown (Clarkson Potter, October 12, 2012) – ISBN 978-0-3077-1916-4 Bobby Flay's Barbecue Addiction (Clarkson Potter, April 23, 2013) – ISBN 978-0-3074-6139-1 Bobby Flay Fit: 200 Recipes for a Healthy Lifestyle (Co-authors: Stephanie Banyas and Sally Jackson; Publisher – Clarkson Potter, December 5, 2017) - ISBN 978-0-3853-4593-4 Bobby at Home: Fearless Flavors from My Kitchen (Clarkson Potter, September 24, 2019) – ISBN 978-0-3853-4591-0
Reducing information asymmetry: Price information affects competitive markets' efficiency because it impacts price dispersion, arbitrage, and farmer and consumer welfare. Since the marginal cost of digitally delivering information approaches zero, digital agriculture has the potential to spread price information. Aker and Fafchamps find that the introduction of mobile phone coverage in Niger reduced spatial price dispersion for agri-food products, especially for remote markets and perishable goods. Similarly, price information provided by Internet kiosks ("e-choupals") in India led to an increase in farmers' net profits as traders lost monopsony power. Other examples of digital platforms for price information include MFarm and Esoko. Matching buyers and sellers: E-commerce lowers the search costs of matching buyers and sellers, potentially shortening the value chain. Rather than go through dozens of intermediaries, farmers can sell directly to consumers. Market access services can also solve the matching problem without necessarily hosting online transactions. For example, Esoko sends market information (prices for specific commodities, market locations, etc.) to agents and farmers, connecting them to commodity buyers. All of these matching platforms help smallholders coordinate with buyers and enter both regional and global value chains. Finally, digital technologies can also facilitate matching in financial and input markets, not just producer-to-consumer output sales.
Sources: en.wikipedia.org
It may lead to brain tumors such as astrocytomas. In some of the late-onset neurodegenerative diseases that share aggregation of misfolded proteins as a common feature, such as Parkinson's disease and Alzheimer's disease, large insoluble aggregates of misfolded proteins can form and then result in neurotoxicity, through mechanisms that are not yet well understood. Decreased proteasome activity has been suggested as a cause of aggregation and Lewy body formation in Parkinson's. This hypothesis is supported by the observation that yeast models of Parkinson's are more susceptible to toxicity from α-synuclein, the major protein component of Lewy bodies, under conditions of low proteasome activity. Impaired proteasomal activity may underlie cognitive disorders such as the autism spectrum disorders, and muscle and nerve diseases such as inclusion body myopathy.
== See also == Classification of personality disorders Identity disturbance – Deficiency or inability to maintain one or more major components of identity Otto Kernberg – Founder of Transference-Focused Psychotherapy (TFP)Pages displaying short descriptions of redirect targets
=== Dicastery for the Causes of Saints === As part of his 2022 reorganization of the Curia in Praedicate evangelium, Pope Francis renamed the congregation to the Dicastery for the Causes of Saints. It is working on about 1,600 causes, some dating from the 15th century.
==== Ethanol distillation ==== Graphene oxide membranes allow water vapor to pass through, but are impermeable to other liquids and gases. This phenomenon has been used for further distilling of vodka to higher alcohol concentrations, in a room-temperature laboratory, without the application of heat or vacuum as used in traditional distillation methods. Further development and commercialization of such membranes could revolutionize the economics of biofuel production and the alcoholic beverage industry.
=== EC 1.14.12 With NADH or NADPH as one donor, and incorporation of two atoms of oxygen into one donor === EC 1.14.12.1: anthranilate 1,2-dioxygenase (deaminating, decarboxylating) EC 1.14.12.2: Now EC 1.14.13.35 anthranilate 3-monooxygenase (deaminating) EC 1.14.12.3: benzene 1,2-dioxygenase EC 1.14.12.4: EC 1.14.13.242, 3-hydroxy-2-methylpyridinecarboxylate monooxygenase EC 1.14.12.5: Now EC .14.13.241, 5-pyridoxate monooxygenase EC 1.14.12.6: Now EC 1.14.13.66, 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.12.7: phthalate 4,5-dioxygenase EC 1.14.12.8: 4-sulfobenzoate 3,4-dioxygenase EC 1.14.12.9: 4-chlorophenylacetate 3,4-dioxygenase EC 1.14.12.10: benzoate 1,2-dioxygenase EC 1.14.12.11: toluene dioxygenase EC 1.14.12.12: naphthalene 1,2-dioxygenase EC 1.14.12.13: 2-halobenzoate 1,2-dioxygenase EC 1.14.12.14: 2-aminobenzenesulfonate 2,3-dioxygenase EC 1.14.12.15: terephthalate 1,2-dioxygenase EC 1.14.12.16: 2-hydroxyquinoline 5,6-dioxygenase EC 1.14.12.17: nitric oxide dioxygenase EC 1.14.12.18: biphenyl 2,3-dioxygenase EC 1.14.12.19: 3-phenylpropionate dioxygenase EC 1.14.12.20: Now classified as EC 1.14.15.17, pheophorbide a oxygenase. EC 1.14.12.21: Now EC 1.14.13.208, benzoyl-CoA 2,3-epoxidase EC 1.14.12.22: carbazole 1,9a-dioxygenase EC 1.14.12.23: nitroarene dioxygenase EC 1.14.12.24: 2,4-dinitrotoluene dioxygenase EC 1.14.12.25: p-cumate 2,3-dioxygenase EC 1.14.12.26: chlorobenzene dioxygenase
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.